Renovis Announces Results of REN-1654 Study for Post-Herpetic Neuralgia

Renovis, a biopharmaceutical company focused on the discovery and development of drugs to treat neurological diseases and disorders, has announced results of its Phase II clinical trial studying REN-1654 in patients with post-herpetic neuralgia.

The results indicate that REN-1654 did not reach statistical significance in its primary endpoint of change in daily spontaneous pain relief. Based on the results of the study, Renovis is discontinuing development of REN-1654 in PHN.

The company is continuing enrollment as planned in its second Phase II clinical trial with REN-1654 studying patients with sciatica. REN-1654 is an orally administered TNF-alpha release inhibitor which has shown activity in animal models of neuropathic pain.